000 | 05240cam a2200757Ka 4500 | ||
---|---|---|---|
001 | ocn739120274 | ||
003 | OCoLC | ||
005 | 20220701010832.0 | ||
006 | m o d | ||
007 | cr cn||||||||| | ||
008 | 110706s2011 nju ob 000 0 eng | ||
010 | _z 2011002984 | ||
040 |
_aDG1 _beng _epn _cDG1 _dE7B _dOCLCQ _dCDX _dYDXCP _dN$T _dOCLCQ _dOCLCF _dOCLCA _dOCLCQ _dNLGGC _dOCLCQ _dEBLCP _dOCLCQ _dDEBBG _dAZK _dLOA _dOCLCO _dOCLCA _dMERER _dOCLCO |
||
019 |
_a747412453 _a751680753 _a758670738 _a961555913 _a962625736 _a966204491 |
||
020 | _a9781118075685 | ||
020 | _a1118075684 | ||
020 |
_a9781118075661 _q(e-book) |
||
020 |
_a1118075668 _q(e-book) |
||
020 |
_a0470566663 _q(Cloth) |
||
020 |
_a9780470566664 _q(Cloth) |
||
020 |
_z9780470566664 _q(cloth) |
||
020 |
_z9781118075678 _q(ePub) |
||
024 | 8 | _a9786613203854 | |
029 | 1 |
_aAU@ _b000049163109 |
|
029 | 1 |
_aAU@ _b000053280047 |
|
029 | 1 |
_aDKDLA _b820120-katalog:000571996 |
|
029 | 1 |
_aDKDLA _b830060-katalog:10484657 |
|
029 | 1 |
_aDKDLA _b860900-katalog:10484657 |
|
029 | 1 |
_aNZ1 _b15915613 |
|
029 | 1 |
_aDEBBG _bBV043393313 |
|
035 |
_a(OCoLC)739120274 _z(OCoLC)747412453 _z(OCoLC)751680753 _z(OCoLC)758670738 _z(OCoLC)961555913 _z(OCoLC)962625736 _z(OCoLC)966204491 |
||
037 |
_a10.1002/9781118075685 _bWiley InterScience _nhttp://www3.interscience.wiley.com |
||
050 | 4 |
_aQR186.7 _b.D48 2011 |
|
060 | 4 | _aQW 575 | |
072 | 7 |
_aMED _x044000 _2bisacsh |
|
082 | 0 | 4 |
_a616.07/98 _223 |
049 | _aMAIN | ||
245 | 0 | 0 |
_aDetection and quantification of antibodies to biopharmaceuticals : _bpractical and applied considerations / _c[edited] by Michael G. Tovey. |
260 |
_aHoboken, N.J. : _bWiley, _c©2011. |
||
300 | _a1 online resource (xxiii, 404 pages) | ||
336 |
_atext _btxt _2rdacontent |
||
337 |
_acomputer _bc _2rdamedia |
||
338 |
_aonline resource _bcr _2rdacarrier |
||
347 |
_adata file _2rda |
||
380 | _aBibliography | ||
504 | _aIncludes bibliographical references. | ||
505 | 0 | _aPrincipals of risk assessment and monitoring of antibody responses to biopharmaceuticals / Eugen Koren, Erik Foehr, and Charles A. O'Neill -- Immunogenicity of therapeutic proteins : a regulatory perspective / Susan Kirshner -- Guidance on immunogenicity assessment of biologically-derived therapeutic proteins : an European perspective / Meenu Wadhwa and Robin Thorpe -- Japanese regulatory perspective on immunogenicity / Takao Hayakawa and Akiko Ishii -- Enzyme immunoassays and radioimmune assays for quantification of anti-TNF biopharmaceuticals and anti-drug antibodies / Klaus Bendtzen and Morten Svenson -- Confirmatory immunogenicity assays / Eric Wakshull and Daniel Coleman -- The use of pharmacodynamics as a surrogate marker for the detection of anti-drug neutralizing antibodies / Florian Deisenhammer -- Cell-based assays for the detection of neutralizing antibodies to interferon beta (IFN-?) and tumor necrosis factor-alpha (TNF-?) inhibitors / Anthony Meager -- Detection of neutralizing antibodies (NABs) to Interferon-beta by real time RT-PCR / Francesca Gilli and Antonio Bertolotto -- Competitive ligand binding assays for the detection of neutralizing antibodies / Bonnie Wu, George R. Gunn III, and Gopi Shankar. | |
505 | 0 | _aThe use of surface plasmon resonance for the detection and characterization of antibodies / Steven J. Swanson and Daniel Mytych -- Hypersensitivity reactions to biopharmaceuticals : detection and quantification of drug-specific IgE antibodies / Jørgen Dahlstrøm and Lennart Venemalm -- Standardization and validation of immunoassays and biophysical assays for the detection of anti-drug antibodies / Daniel Kramer -- Standardization and validation of cell-based assays for the detection of neutralizing anti-drug antibodies / Deborah Finco-Kent and Amy Grenham -- Standardization of neutralizing antibody unitge by bioassay design : constant antigen and constant antibody methodology / Sidney E. Grossberg, Yoshimi Kawade, and Leslie D. Grossberg -- Cut-points and performance characteristics for anti-drug antibody assays / Viswanath Devanarayan and Michael G. Tovey -- Dilutional linearity for neutralizing antibody assays / David Lansky and Carrie Wager -- Detection of neutralizing antibodies to biopharmaceuticals in the presence of high levels of circulating drug / Arno Kromminga and Michael G. Tovey. | |
588 | 0 | _aPrint version record. | |
650 | 0 |
_aImmunoglobulins _xAnalysis. |
|
650 | 0 | _aImmunoassay. | |
650 | 7 |
_aMEDICAL _xImmunology. _2bisacsh |
|
650 | 7 |
_aImmunoassay. _2fast _0(OCoLC)fst00967921 |
|
650 | 7 |
_aImmunoglobulins _xAnalysis. _2fast _0(OCoLC)fst00967962 |
|
650 | 2 |
_aAntibodies, Neutralizing _xanalysis. |
|
650 | 2 |
_aAntibodies, Neutralizing _ximmunology. |
|
650 | 2 |
_aBiological Factors _ximmunology. |
|
650 | 2 |
_aImmunoassay _xmethods. |
|
655 | 4 | _aElectronic books. | |
655 | 7 |
_aElectronic books. _2local |
|
700 | 1 | _aTovey, Michael G. | |
710 | 2 | _aWiley InterScience (Online service) | |
776 | 0 | 8 |
_iPrint version: _tDetection and quantification of antibodies to biopharmaceuticals. _dHoboken, N.J. : Wiley, ©2011 _w(DLC) 2011002984 |
856 | 4 | 0 |
_uhttp://dx.doi.org/10.1002/9781118075685 _zWiley Online Library |
994 |
_a92 _bDG1 |
||
999 |
_c18806 _d18765 |